Telmisartan Capsules

Not yet clear.

4'-[(2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)methyl]diphenyl-2-carboxylic acid = Telmisartan

This product is a capsule, and the contents are white or off-white granules or powder.

Used for the treatment of essential hypertension.

1. Adults: Individualized medication should be used. The usual initial dose is one tablet (40 mg) once a day. Within the dose range of 20-80 mg, the antihypertensive effect of telmisartan is related to the dose. If the ideal blood pressure is not achieved after medication, the dose can be increased, and the maximum dose is 80 mg (two tablets) once a day. This product can be used in combination with thiazide diuretics such as hydrochlorothiazide, which have a synergistic antihypertensive effect with this product. Because telmisartan can only exert its maximum efficacy four to eight weeks after the start of the treatment, if you want to increase the drug dose, this should be considered. 2. Patients with renal insufficiency, patients with mild or moderate renal dysfunction, do not need to adjust the dose of this product. Telmisartan cannot be eliminated by hemodialysis. 3. Patients with hepatic insufficiency, patients with mild or moderate hepatic insufficiency, the daily dosage of this product should not exceed 40 mg. 4. Elderly: No dose adjustment is required for taking this product. 5. Children: The safety and efficacy data of this product have not been established for children and adolescents under 18 years of age.

Diarrhea and angioedema. Most of them are mild and temporary, and generally do not require discontinuation of treatment. Their occurrence is not related to dose.

1. Those who are allergic to the active ingredients and any of the excipients of this product. 2. Those in the second or third trimester of pregnancy and breastfeeding. 3. Patients with biliary obstructive diseases. 4. Patients with severe liver dysfunction. 5. Patients with severe renal dysfunction (creatinine clearance 30ml/min).

Precautions for children: For children and adolescents under 18 years old, the safety and efficacy data of this product have not been established. Precautions for pregnancy and lactation: 1. Use during pregnancy: There is not enough data to show whether this product can be used in pregnant women. Animal experiments did not show teratogenicity, but showed embryotoxicity. Therefore, for the sake of caution, do not use telmisartan in the first two months of pregnancy. Before planning pregnancy, appropriate alternative therapies should be taken. In the middle and late stages of pregnancy (during the second and third trimesters), drugs that directly act on the renin-angiotensin system can cause damage to the fetus or even death, so telmisartan is contraindicated in the middle and late stages of pregnancy. Once pregnancy is confirmed, this product should be discontinued as soon as possible. 2. Use during lactation: Since it is unknown whether this product is excreted through breast milk, this product is contraindicated during lactation. Precautions for the elderly: No dosage adjustment is required when taking this product.

1. Lithium punishment: The combination of lithium and angiotensin converting enzyme inhibitors can cause reversible increases in blood lithium levels and toxic reactions. There are also individual cases caused by the combination of lithium and angiotensin II receptor antagonists. Therefore, lithium and this product should be used with caution. If combined use is necessary, blood lithium levels should be monitored during the combined use. 2. Some drugs can affect blood potassium levels or cause hyperkalemia (such as ACE inhibitors, potassium-sparing diuretics, potassium ion supplements, potassium-containing salt substitutes, cyclosporine A or other drugs such as heparin sodium); if this product needs to be used in combination with these drugs, it is recommended to test blood potassium levels. Based on the experience of using other drugs that affect the renin-angiotensin system, this product combined with the above drugs can cause an increase in blood potassium levels (see Precautions). 3. Pharmacokinetic studies have studied the interaction of this product with digoxin, warfarin, hydrochlorothiazide, glibenclamide, ibuprofen, paracetamol, amlodipine and other drugs. It can increase the average trough blood concentration of digoxin by 20% (in some cases by 39%), so the digoxin plasma concentration must be clinically measured. 4. This product can enhance the antihypertensive effect of other antihypertensive drugs. Other clinically significant interactions have not yet been confirmed. 5. Based on their pharmacological properties, the following drugs can enhance the antihypertensive effect of antihypertensive drugs including telmisartan: baclofen, amifostine. In addition, alcohol, barbiturates, sedatives, hypnotics or antidepressants can enhance the orthostatic hypotension effect. 6. When used in combination with telmisartan, the Cmax of simvastatin metabolites (simvastatin acid) is slightly increased (1.34 times) and the elimination is accelerated.

Store at room temperature in a dry place.

20mg

24 months

Yunnan Lanlukang Pharmaceutical Co., Ltd.

• Founded in:

  1999-07-26

• Address:

  No. 176, Keyi Road, High-tech Industrial Development Zone, Kunming, Yunnan Province

• Tax NO.:

  915301007134388620

• Registered Funds:

  68 million yuan

• Website:

  Log in to view

• Email:

  Log in to view